X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5622) 5622
Publication (566) 566
Book Review (133) 133
Newsletter (83) 83
Book Chapter (58) 58
Newspaper Article (47) 47
Magazine Article (33) 33
Book / eBook (15) 15
Dissertation (7) 7
Conference Proceeding (6) 6
Data Set (5) 5
Transcript (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3890) 3890
index medicus (3049) 3049
proton pump inhibitors (2727) 2727
male (2338) 2338
female (1971) 1971
middle aged (1458) 1458
gastroenterology & hepatology (1298) 1298
pharmacology & pharmacy (1292) 1292
adult (1248) 1248
animals (1175) 1175
aged (1171) 1171
omeprazole (1119) 1119
proton pump inhibitors - therapeutic use (983) 983
proton pump inhibitor (808) 808
risk factors (719) 719
treatment outcome (684) 684
lansoprazole (581) 581
medicine & public health (570) 570
proton pump inhibitors - adverse effects (548) 548
helicobacter pylori (497) 497
hydrogen-ion concentration (484) 484
proton pump inhibitors - administration & dosage (474) 474
care and treatment (471) 471
therapy (448) 448
pharmacokinetics (442) 442
drug interactions (432) 432
research (432) 432
aged, 80 and over (423) 423
health aspects (417) 417
protons (410) 410
helicobacter infections - drug therapy (409) 409
rats (401) 401
gastroesophageal reflux (399) 399
drug therapy, combination (397) 397
analysis (391) 391
risk (383) 383
anti-ulcer agents - therapeutic use (381) 381
internal medicine (364) 364
drug therapy (362) 362
pantoprazole (356) 356
2-pyridinylmethylsulfinylbenzimidazoles (354) 354
proton-pump inhibitors (349) 349
oncology (344) 344
young adult (344) 344
gastroesophageal reflux - drug therapy (343) 343
prospective studies (340) 340
gastroenterology (334) 334
adolescent (329) 329
proton pump inhibitors - pharmacology (325) 325
medicine, general & internal (322) 322
double-blind (318) 318
omeprazole - analogs & derivatives (318) 318
rabeprazole (315) 315
retrospective studies (308) 308
endoscopy (300) 300
abridged index medicus (295) 295
time factors (294) 294
article (293) 293
cancer (292) 292
gastroesophageal-reflux disease (289) 289
diagnosis (285) 285
anti-bacterial agents - therapeutic use (284) 284
disease (282) 282
metabolism (277) 277
omeprazole - therapeutic use (274) 274
mice (271) 271
clopidogrel (267) 267
helicobacter-pylori infection (264) 264
ulcers (263) 263
omeprazole - pharmacology (261) 261
dose-response relationship, drug (259) 259
dosage and administration (258) 258
cell biology (255) 255
esomeprazole (252) 252
nonsteroidal antiinflammatory drugs (251) 251
physiology (249) 249
administration, oral (248) 248
complications and side effects (248) 248
aspirin (247) 247
infection (247) 247
management (243) 243
biochemistry & molecular biology (241) 241
drugs (241) 241
ticlopidine - analogs & derivatives (241) 241
surgery (240) 240
pharmacology/toxicology (239) 239
physiological aspects (239) 239
prevention (231) 231
double-blind method (230) 230
anti-ulcer agents - administration & dosage (226) 226
peptic ulcer (225) 225
mortality (223) 223
prevalence (222) 222
medicine (221) 221
omeprazole - administration & dosage (221) 221
patients (221) 221
cross-over studies (219) 219
pharmacology (219) 219
gastroesophageal reflux disease (215) 215
studies (211) 211
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5737) 5737
French (18) 18
German (18) 18
Spanish (17) 17
Russian (16) 16
Japanese (13) 13
Korean (9) 9
Chinese (6) 6
Ukrainian (3) 3
Dutch (2) 2
Italian (2) 2
Polish (2) 2
Finnish (1) 1
Hungarian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation, ISSN 0009-7322, 02/2012, Volume 125, Issue 8, pp. 978 - 986
Journal Article
American Journal of Kidney Diseases, ISSN 0272-6386, 2010, Volume 56, Issue 1, pp. 112 - 116
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 02/2018, Volume 103, Issue 2, pp. 217 - 223
Only limited data are available regarding the treatment of critically ill patients with clopidogrel. This trial investigated the effects and the drug... 
PHARMACODYNAMIC RESPONSES | POLYMORPHISMS | PHARMACOKINETICS | HIGH-DOSE CLOPIDOGREL | ACUTE MYOCARDIAL-INFARCTION | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | TREATMENT PLATELET REACTIVITY | PRASUGREL | CYP2C19 | CORONARY-ARTERY-DISEASE | Activation, Metabolic | Clopidogrel - blood | Humans | Middle Aged | Critical Illness | Half-Life | Male | Microfilament Proteins - blood | Clopidogrel - administration & dosage | Drug Monitoring - methods | Clopidogrel - pharmacokinetics | Pantoprazole - administration & dosage | Platelet Aggregation Inhibitors - blood | Austria | Pantoprazole - pharmacokinetics | Phosphoproteins - blood | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Platelet Function Tests | Female | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Proton Pump Inhibitors - blood | Blood Platelets - drug effects | Drug Resistance | Platelet Aggregation Inhibitors - adverse effects | Cell Adhesion Molecules - blood | Proton Pump Inhibitors - adverse effects | Down-Regulation | Cytochrome P-450 CYP2C19 - genetics | Biomarkers - blood | Pantoprazole - blood | Proton Pump Inhibitors - pharmacokinetics | Blood Platelets - metabolism | Pantoprazole - adverse effects | Cytochrome P-450 CYP2C19 - metabolism | Aged | Clopidogrel - adverse effects | Care and treatment | Usage | Critically ill | Clopidogrel | Cytochromes | Research | Health aspects | Clinical Trial
Journal Article
Journal of Arrhythmia, ISSN 1880-4276, 12/2017, Volume 33, Issue 6, pp. 619 - 623
Dabigatran is a direct thrombin inhibitor used to decrease the risk of ischemic stroke in patients with non-valvular atrial fibrillation (NVAF). Its prodrug,... 
Drug–drug interaction | Dabigatran | Proton pump inhibitor | Studies | Anticoagulants | Cardiac arrhythmia | Laboratories | Embolisms | Patients | Clinical outcomes | Original
Journal Article
Advances in Experimental Medicine and Biology, ISSN 0065-2598, 01/2017, Volume 906, pp. 325 - 350
Aspirin and P2Y(12) receptor antagonists are widely used across the spectrum of cardiovascular diseases. Upper gastrointestinal complications, including ulcer... 
Clopidogrel | Proton pump inhibitors | Aspirin | ADP receptor antagonists | Drug interactions | ACETYLSALICYLIC-ACID | MEDICINE, RESEARCH & EXPERIMENTAL | ACID 325 MG | PLATELET-FUNCTION | ACUTE CORONARY SYNDROMES | ESOMEPRAZOLE 40 MG | ENTERIC-COATED ASPIRIN | CONCOMITANT USE | COMBINING ASPIRIN | LOW-DOSE ASPIRIN | ACUTE MYOCARDIAL-INFARCTION | PERIPHERAL VASCULAR DISEASE | Cardiovascular Diseases - drug therapy | Humans | Aspirin - pharmacokinetics | Esomeprazole - blood | Cardiovascular Diseases - pathology | Cardiovascular Diseases - genetics | Drug Dosage Calculations | Drug Interactions | Gastrointestinal Hemorrhage - metabolism | Adenosine - therapeutic use | Hydrogen-Ion Concentration - drug effects | Ticlopidine - pharmacokinetics | Proton Pump Inhibitors - blood | Purinergic Antagonists - pharmacokinetics | Receptors, Purinergic P2Y12 - metabolism | Receptors, Purinergic P2Y12 - genetics | Gene Expression | Purinergic Antagonists - blood | Cardiovascular Diseases - metabolism | Drug Administration Schedule | Aspirin - blood | Esomeprazole - pharmacokinetics | Peptic Ulcer - metabolism | Peptic Ulcer - pathology | Ticlopidine - analogs & derivatives | Prasugrel Hydrochloride - therapeutic use | Gastrointestinal Hemorrhage - chemically induced | Proton Pump Inhibitors - pharmacokinetics | Adenosine - analogs & derivatives | Peptic Ulcer - chemically induced | Gastrointestinal Hemorrhage - pathology | Ticlopidine - blood
Journal Article
Biomedical Chromatography, ISSN 0269-3879, 08/2015, Volume 29, Issue 8, pp. 1203 - 1212
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 9/2018, Volume 74, Issue 9, pp. 1149 - 1157
Ilaprazole, the latest proton pump inhibitor, can be used with clarithromycin and amoxicillin as a triple therapy regimen for eradicating Helicobacter pylori.... 
Clarithromycin | Biomedicine | Amoxicillin | Drug interaction | Ilaprazole | Pharmacology/Toxicology | Pharmacokinetics | Proton pump inhibitor | DUODENAL-ULCER | OMEPRAZOLE | PLASMA | DOUBLE-BLIND | TRIPLE THERAPY | PHARMACOLOGY & PHARMACY | ERADICATION | CURE | HEALTHY-VOLUNTEERS | HELICOBACTER-PYLORI | Anti-Bacterial Agents - blood | Humans | Middle Aged | Helicobacter pylori - drug effects | Male | Healthy Volunteers | Clarithromycin - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Helicobacter Infections - drug therapy | Clarithromycin - pharmacokinetics | Patient Safety | Clarithromycin - administration & dosage | Adult | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Proton Pump Inhibitors - blood | Drug Therapy, Combination | Republic of Korea | Proton Pump Inhibitors - adverse effects | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacokinetics | Risk Assessment | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Clarithromycin - adverse effects | Amoxicillin - blood | Amoxicillin - pharmacokinetics | Cross-Over Studies | Proton Pump Inhibitors - pharmacokinetics | Anti-Bacterial Agents - pharmacokinetics | Amoxicillin - adverse effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Anti-Bacterial Agents - administration & dosage | 2-Pyridinylmethylsulfinylbenzimidazoles - blood | Helicobacter Infections - microbiology | Complications and side effects | Dosage and administration | Safety and security measures | Drug interactions | Confidence intervals | Therapy | Randomization | Statistical analysis | Helicobacter pylori | Pharmacology | Safety | Pharmacokinetics and Disposition
Journal Article
Journal Article
Journal Article
Journal Article
The AAPS Journal, ISSN 0006-8101, 11/2014, Volume 16, Issue 6, pp. 1358 - 1365
Many orally administered, small-molecule, targeted anticancer drugs, such as dasatinib, exhibit pH-dependent solubility and reduced drug exposure when given... 
Biochemistry, general | Biotechnology | proton pump inhibitors | drug-drug interactions | Biomedicine | dasatinib | pH-dependent solubility | Pharmacy | betaine hydrochloride | Pharmacology/Toxicology | PH-dependent solubility | Betaine hydrochloride | Dasatinib | Proton pump inhibitors | Drug-drug interactions | EFFICACY | OMEPRAZOLE | PROTON-PUMP INHIBITORS | SOLUBILITY | PHARMACOKINETICS | BEVERAGE COCA-COLA | PHARMACOLOGY & PHARMACY | ATAZANAVIR | LEUKEMIA | Proton Pump Inhibitors - pharmacology | Thiazoles - blood | Gastric Acid - chemistry | Area Under Curve | Pyrimidines - blood | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Antineoplastic Agents - administration & dosage | Healthy Volunteers | Achlorhydria - chemically induced | Thiazoles - pharmacokinetics | Young Adult | Rabeprazole - blood | Rabeprazole - pharmacokinetics | Betaine - administration & dosage | Drug Interactions | Adult | Female | Antineoplastic Agents - pharmacokinetics | Proton Pump Inhibitors - blood | Absorption, Physiological - drug effects | Pyrimidines - administration & dosage | Achlorhydria - metabolism | Betaine - pharmacology | Cross-Over Studies | Proton Pump Inhibitors - pharmacokinetics | Rabeprazole - pharmacology | Antineoplastic Agents - blood | Pyrimidines - pharmacokinetics | Hydrogen-Ion Concentration | Usage | Drug interactions | Rabeprazole
Journal Article
Journal Article
Journal Article